HGF and uveal melanoma: These data suggest that the MAPK and PI3K pathways may be activated by high levels of HGF, which decreases the efficacy of darovasertib, and this can be overcome by incubating the two uveal melanoma cell lines with crizotinib, a MET inhibitor (Camidge et al., 2014).